ACHC launches accreditation distinction for Ig therapy
By HME News Staff
Updated 9:44 AM CDT, Wed March 18, 2026
CARY, N.C. – The Accreditation Commission for Health Care (ACHC) has partnered with the Immunoglobulin National Society (IgNS) to launch the Distinction in Immunoglobulin Therapy. This new distinction offers specialty and infusion pharmacies a formal path to demonstrate advanced clinical and operational excellence in the delivery of immunoglobulin (Ig) therapy across all sites of care. “This partnership is an important step toward improving patient safety in Ig therapy,” said Matt Hughes, vice president of ACHC Community Care Services. “IgNS is the only national standards-setting organization dedicated to advancing the practice of Ig therapy and biologics across clinical specialties and sites of care. The society’s focus on clinician preparation and competencies is an ideal complement to ACHC’s focus on achievement and maintenance of quality and safety standards at the organizational level.” Developed in response to the growing demand for clinical excellence, safety, efficacy and accountability, the distinction ensures the delivery of life-saving Ig therapy to patients with multiple immune-mediated disorders. As the highly specialized field of Ig therapy continues to expand due to improved diagnostic methodologies, new clinical indications and increasing access across sites of care, formal accreditation parameters are crucial to guide practice, ensure safety, and reinforce best practices across the continuum of care, ACHC says.
Comments